Nicholas D. P. Cosford

This paper reports the discovery of SBP-5917, a reversible FASN-TE inhibitor with submicromolar potency and cellular target engagement.

The paper reports the design, synthesis, and characterization of new ULK1/2 inhibitors that inhibit autophagy and upregulate MHC I in NSCLC cells, supporting their potential as cancer therapeutics.

The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.

This study identifies metabolic adaptations in pancreatic cancer cells resistant to autophagy inhibitors and shows that targeting pyrimidine salvage can enhance treatment efficacy.

This study shows that low estrogen in female rats increases sensitivity to NMDAR antagonists and reduces antipsychotic effectiveness, with GluN2A expression playing a key role.